Detalhe da pesquisa
1.
Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial.
J Am Acad Dermatol
; 2024 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38556093
2.
Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial.
Am J Clin Dermatol
; 24(2): 305-313, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36370336
3.
Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial.
JAMA Dermatol
; 159(6): 613-620, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37133856
4.
Long-term efficacy of up to 15 months' efalizumab therapy in patients with moderate-to-severe chronic plaque psoriasis.
Dermatol Ther
; 21 Suppl 3: S6-14, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-19076630
5.
Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study.
Int J Dermatol
; 46(6): 637-48, 2007 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-17550570